Raymond James Financial Inc. bought a new position in shares of Acadia Healthcare Company, Inc. (NASDAQ:ACHC - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 129,486 shares of the company's stock, valued at approximately $5,134,000. Raymond James Financial Inc. owned 0.14% of Acadia Healthcare at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its position in shares of Acadia Healthcare by 12.2% in the third quarter. Wellington Management Group LLP now owns 11,658,253 shares of the company's stock worth $739,250,000 after acquiring an additional 1,266,384 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Acadia Healthcare by 17.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,126,607 shares of the company's stock valued at $198,258,000 after purchasing an additional 454,044 shares during the last quarter. State Street Corp grew its stake in shares of Acadia Healthcare by 3.5% during the 3rd quarter. State Street Corp now owns 2,819,911 shares of the company's stock valued at $178,811,000 after buying an additional 95,613 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Acadia Healthcare by 0.5% during the 3rd quarter. Point72 Asset Management L.P. now owns 2,282,810 shares of the company's stock worth $144,753,000 after buying an additional 12,470 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Acadia Healthcare by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,613,198 shares of the company's stock worth $102,320,000 after buying an additional 14,197 shares during the period.
Analyst Upgrades and Downgrades
Several brokerages have commented on ACHC. Bank of America dropped their price target on Acadia Healthcare from $50.00 to $44.50 and set a "buy" rating for the company in a research note on Friday, February 28th. TD Cowen dropped their target price on shares of Acadia Healthcare from $70.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday, January 7th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $52.00 price target on shares of Acadia Healthcare in a research report on Tuesday, December 10th. KeyCorp dropped their price objective on shares of Acadia Healthcare from $70.00 to $65.00 and set an "overweight" rating for the company in a research report on Monday, March 3rd. Finally, Mizuho decreased their price target on shares of Acadia Healthcare from $48.00 to $37.00 and set a "neutral" rating for the company in a research report on Tuesday. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $52.19.
View Our Latest Analysis on Acadia Healthcare
Acadia Healthcare Price Performance
ACHC remained flat at $30.12 during trading hours on Friday. 1,521,599 shares of the company were exchanged, compared to its average volume of 1,383,810. Acadia Healthcare Company, Inc. has a 1-year low of $27.61 and a 1-year high of $82.41. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.60. The firm has a market cap of $2.80 billion, a P/E ratio of 9.88, a price-to-earnings-growth ratio of 1.46 and a beta of 1.38. The business's fifty day moving average price is $37.14 and its two-hundred day moving average price is $45.06.
Acadia Healthcare Profile
(
Free Report)
Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.
Further Reading

Before you consider Acadia Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acadia Healthcare wasn't on the list.
While Acadia Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.